Contact Us
Drug Search Results
More Filters [+]

GP100:209-217

Alternative Names: gp100:209-217, gp100:209217, gp100:209 217
Latest Update: 2023-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GP100:209-217

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MCC-15280

P1

Completed

Melanoma

2012-04-01

Recent News Events

Date

Type

Title

02/01/2023

PubMed

 ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes.

02/01/2020

PubMed

 ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions